111 related articles for article (PubMed ID: 38226887)
1. A Lactic Acid Metabolism-Related Gene Signature for Predicting Clinical Outcome and Tumor Microenvironmental Status in Patients with Hepatocellular Carcinoma.
Zhou Z; Wu B; Chen J; Shen Y; Wang J; Chen X; Fei F; Zhu M
Nutr Cancer; 2024; 76(3):279-295. PubMed ID: 38226887
[TBL] [Abstract][Full Text] [Related]
2. A Novel Lactate Metabolism-Related Gene Signature for Predicting Clinical Outcome and Tumor Microenvironment in Hepatocellular Carcinoma.
Li Y; Mo H; Wu S; Liu X; Tu K
Front Cell Dev Biol; 2021; 9():801959. PubMed ID: 35047511
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
4. A lactate metabolism-related signature predicting patient prognosis and immune microenvironment in ovarian cancer.
Zhu L; Lin Z; Wang K; Gu J; Chen X; Chen R; Wang L; Cheng X
Front Endocrinol (Lausanne); 2024; 15():1372413. PubMed ID: 38529390
[TBL] [Abstract][Full Text] [Related]
5. Construction of a lipid metabolism-related risk model for hepatocellular carcinoma by single cell and machine learning analysis.
Mou L; Pu Z; Luo Y; Quan R; So Y; Jiang H
Front Immunol; 2023; 14():1036562. PubMed ID: 36936948
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
7. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatics Analysis of Prognostic Tumor Microenvironment-Related Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Tian Z; Wang Z; Chen Y; Qu S; Liu C; Chen F; Ma L; Zhu J
Med Sci Monit; 2020 Mar; 26():e922159. PubMed ID: 32231177
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
[TBL] [Abstract][Full Text] [Related]
10. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
11. The m
Ma E; Li J; Shen C; Gu Y; Zhang X; Li L; Zhao J; Wang Z
Front Immunol; 2023; 14():1227593. PubMed ID: 37691948
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.
Zhou Y; Li X; Long G; Tao Y; Zhou L; Tang J
Front Immunol; 2022; 13():994259. PubMed ID: 36341373
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
[TBL] [Abstract][Full Text] [Related]
14. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
[TBL] [Abstract][Full Text] [Related]
15. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
16. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
Wang J; Ling S; Ni J; Wan Y
BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
[TBL] [Abstract][Full Text] [Related]
17. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
18. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
19. Machine learning-based integration develops a neutrophil-derived signature for improving outcomes in hepatocellular carcinoma.
Gong Q; Chen X; Liu F; Cao Y
Front Immunol; 2023; 14():1216585. PubMed ID: 37575244
[TBL] [Abstract][Full Text] [Related]
20. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
